Study details
Enrolling now
EVO101 Topical Cream for Hidradenitis Suppurativa
Virginia Clinical Research, Inc.
NCT IDNCT06645821ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
15
Study length
about 6 months
Ages
18+
Locations
1 site in VA
About this study
This trial is testing EVO101, a topical cream, to treat mild to moderate hidradenitis suppurativa in adults. Participants will apply the cream and visit clinics to track their symptoms and disease progression.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take EVO101
PhaseEARLY_Phase 1
Primary goalThe efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO)